We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Travere Therapeutics, Inc.

Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on BioEquity Watch’s Substack. In ...

An established sales force and payer authorization criteria will fuel a fast launch for Travere Therapeutics’ Filspari in its ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Focused on rare disease therapies, this biotech firm reported a notable insider sale amid a year of substantial share price ...

Travere Therapeutics rated a Buy after Filspari’s FDA approval for FSGS—only therapy available. Read TVTX's valuation upside, ...

Ligand Pharmaceuticals snatched up Xoma Royalty in a deal worth $739 million, the companies said Monday as both biotech ...

Piper Sandler analyst Allison Bratzel maintained a Buy rating on Ionis Pharmaceuticals today and set a price target of $100.00. According to TipRanks, Bratzel is a 5-star analyst with an average ...

The Summers Value Fund LP returned 6.7% net in 2025, trailing Russell 2000 Index ETF, which returned 12.7%, and Russell 2000 ...

"AstraZeneca to seek accelerated approval of Ultomirisin in IgAN on Phase III data" was originally created and published by ...

AstraZeneca announced in May 2026 that its drug Ultomiris significantly reduced urine protein levels in patients with IgA ...

Already approved to treat four rare diseases, AstraZeneca’s Ultomiris has shown its ability against another rare disorder, ...